This indicates that targeting HER2 therapy has a strong potential for treating metastatic colorectal cancer (Meric-Bernstam et al., 2019; Sartore-Bianchi et al., 2020; Siena et al., 2021). This evidence concerns the gene ERBB2 and metastatic colorectal cancer.